A share price of AnaptysBio Inc [ANAB] is currently trading at $17.46, up 3.62%. An important factor to consider is whether the stock is rising or falling in short-term value. The ANAB shares have gain 10.16% over the last week, with a monthly amount glided 24.98%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AnaptysBio Inc [NASDAQ: ANAB] stock has seen the most recent analyst activity on December 11, 2024, when H.C. Wainwright downgraded its rating to a Neutral and also revised its price target to $19 from $52. Previously, BTIG Research downgraded its rating to Neutral on December 02, 2024. On July 22, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $55 on the stock. JP Morgan upgraded its rating to a Overweight and increased its price target to $69 on July 19, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $47 as its price target on April 16, 2024. Wells Fargo started tracking with a Overweight rating for this stock on April 11, 2024, and assigned it a price target of $56. In a note dated March 12, 2024, Wedbush upgraded an Outperform rating on this stock and boosted its target price from $20 to $34.
AnaptysBio Inc experienced fluctuations in its stock price throughout the past year between $12.51 and $41.31. Currently, Wall Street analysts expect the stock to reach $49.83 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $17.46 at the most recent close of the market. An investor can expect a potential return of 185.4% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
Trailing Twelve Months sales for AnaptysBio Inc [NASDAQ:ANAB] were 57.17M which represents 804.67% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -2.58%, Pretax Profit Margin comes in at -2.9%, and Net Profit Margin reading is -2.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -2.88 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.79 points at the first support level, and at 16.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.93, and for the 2nd resistance point, it is at 18.40.
Ratios To Look Out For
To put it in perspective, the Current Ratio for AnaptysBio Inc [NASDAQ:ANAB] is 10.23. On the other hand, the Quick Ratio is 10.23, and the Cash Ratio is 4.37. Considering the valuation of this stock, the price to sales ratio is 9.29, the price to book ratio is 6.30.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on Dec 30 ’24 when 65184.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on Dec 31 ’24 to buy 13268.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 6646.0 shares on Jan 02 ’25.
